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Abstract
Background: The problem of discovering genetic markers as disease signatures is of
great significance for the successful diagnosis, treatment, and prognosis of complex
diseases. Even if many earlier studies worked on identifying disease markers from a
variety of biological resources, they mostly focused on the markers of genes or gene-
sets (i.e., pathways). However, these markers may not be enough to explain biological
interactions between genetic variables that are related to diseases. Thus, in this study,
our aim is to investigate distinctive associations among active pathways (i.e., pathway-
sets) shown each in case and control samples which can be observed from gene
expression and/or methylation data.
Results: The pathway-sets are obtained by identifying a set of associated pathways
that are often active together over a significant number of class samples. For this
purpose, gene expression or methylation profiles are first analyzed to identify significant
(active) pathways via gene-set enrichment analysis. Then, regarding these active
pathways, an association rule mining approach is applied to examine interesting
pathway-sets in each class of samples (case or control). By doing so, the sets of
associated pathways often working together in activity profiles are finally chosen as our
distinctive signature of each class. The identified pathway-sets are aggregated into a
pathway activity network (PAN), which facilitates the visualization of differential
pathway associations between case and control samples. From our experiments with
two publicly available datasets, we could find interesting PAN structures as the
distinctive signatures of breast cancer and uterine leiomyoma cancer, respectively.
Conclusions: Our pathway-set markers were shown to be superior or very comparable
to other genetic markers (such as genes or gene-sets) in disease classification.
Furthermore, the PAN structure, which can be constructed from the identified markers
of pathway-sets, could provide deeper insights into distinctive associations between
pathway activities in case and control samples.
Keywords: Biomarker discovery, Gene expression analysis, Pathway association mining,
Pathway-set markers, Pathway association network
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Background
The problem of finding effective disease markers or signatures is very important for the
successful diagnosis, treatment, and prognosis of complex diseases such as cancers. So
far, many studies have worked on identifying disease-related markers with a variety of
biological resources, such as gene expression profiles [1–8], protein-protein interactions
[9–11], pathway databases [12, 13], and so on. However, most of them focused on
examining the markers of individual genes or gene-sets (i.e., pathways) as disease signa-
tures. For example, such conventional methods like t-tests, fold change, and signal-to-
noise ratio were used to find differentially expressed genes [14–16] without regard to
gene associations or other biological information. On the other hand, some studies ex-
plored gene associations for disease marker findings. For example, Maulik et al. [17]
proposed a rule mining method that employs biclustering analysis to discover interest-
ing relationships among genes under certain conditions. Giugno et al. [18] generated
association rules between gene expression intervals for classification. Other researchers
performed pathway-based analyses to consider the predefined gene-sets (i.e., pathways)
as disease markers [19–25]. Kim et al. [22] introduced pathway-based markers by com-
bining gene-set enrichment analysis with support vector machine. Lee et al. [23] identi-
fied core genes in pathways for disease classification in pathway level.
Although such methods were shown to be very useful in many applications, they may
not be enough to fully understand disease mechanisms. Moreover, multiple candidate
pathways often share some genes, so it leads to forming complex interconnections
among pathways while making analysis and interpretation complicated. For example,
when there are common genes in multiple candidate pathways, they might be consid-
ered to be associated with each other. However, even when multiple candidate path-
ways do not share genes, they may be mutually associated or active together. Thus, it
seems worthwhile to investigate the associations among the activities of significant
pathways differentially shown in case and control samples, as potential disease
signatures.
In this study, our aim is to identify the sets of pathways (i.e., pathway-sets) having as-
sociations in the activities observed from gene expression profiles (or DNA methylation
data), especially shown differentially in case and control samples. For this purpose, we
utilized an association rule mining approach to find active pathway-sets that are shown
distinctively and frequently in each class of samples (case or control). This was done
based on the assumption that the set of pathways often being active together in gene
expression (or methylation) profiles could have some interesting biological relationships
among them. For the discovery of interesting pathway-sets, we conducted gene-set en-
richment analysis (GSEA) [26] to identify significant (active) pathways and derived
pathway activity profiles from gene expression (or methylation) data. Then, we applied
the BiMax clustering on the pathway activity profiles to detect clusters of co-activated
pathways frequently shown in class samples. In the end, interesting pathway-sets were
found by taking the significant sets of co-activated pathways that satisfy a certain
threshold of significance measures. For the evaluation of the identified pathway-sets,
we used them as disease markers for classification and analyzed the performance. Be-
sides, we aggregated the inferred pathway-sets in each class into a pathway activity net-
work (PAN) in which nodes represent significant active pathways and edges represent
interesting associations between the pathways. This PAN facilitates the visualization of
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differential pathway associations shown in case and control samples. Figure 1 summa-
rizes the overall workflow of our pathway association mining approach used in this
study.
Results and discussion
For experiments, we utilized two publicly available cancer datasets in this study.
GSE15852 [27] (Dataset 1) is the gene expression data about breast cancer, which in-
cludes 86 samples (43 controls, 43 cases) of 12,500 probes. GSE31699 [28] (Dataset 2)
is the dataset for uterine leiomyoma cancer that contains mRNA expression profiles of
48,803 probes in 16 uterine leiomyoma tumor (LM) samples and 16 normal myometrial
(MM) samples and DNA methylation profiles of 27,578 probes in18 uterine LM sam-
ples and 18 normal MM samples.
Identification of pathway-set markers in breast tumors and paired normal tissues
In breast cancer dataset (Dataset 1), we first identified 36 significant pathways by GSEA
with FDR q-value < 0.05. Then, we produced the activity profiles of these pathways and
utilized them to produce pathway-sets satisfying minimum support of 25%. (See the
Methods section for details) Out of these pathway-sets, we have chosen top 250 signifi-
cant pathway-sets in each class as disease markers for further analyses. Figure 2 shows
Fig. 1 The overall workflow for pathway association mining approach in our study
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the heatmap of our 500 pathway-set markers in which the rows represent 36 significant
pathways and the columns represent the activities of 500 pathway-sets. Also up-
regulated pathways are shown in red and down-regulated pathways are shown in blue.
From this figure, we can clearly find the distinctive feature of activities in the chosen
pathway-sets between case and control classes. The details of 36 selected pathways and
top 10 interesting pathway-sets that we identified are given in Additional file 1.
Identification of pathway-set markers in uterine leiomyoma and matched myometrial tissues
In uterine leiomyoma cancer dataset (Dataset 2), we first identified 24 pathways as dif-
ferentially expressed (DE) pathways from gene expression profiles and 25 pathways as
differentially methylated (DM) pathways from methylation data, by using GSEA. Then,
we chose the union of all these pathways (48 pathways) as significant pathways and
used them to detect interesting pathway-sets from gene expression data and methyla-
tion data, respectively. The details of 48 pathways are given in Additional file 2. All the
interesting pathway-sets obtained from gene expression data and methylation data are
shown in Fig. 3(a) and (b), respectively. From this figure, it is seen that the activities of
our chosen pathway-sets are clearly distinguishable between case and control classes.
Also, from these pathway-sets, the relationships between pathway activities shown in
gene expression and methylation data were analyzed. Interestingly, out of 48 pathways,
we could find an inverse relationship between pathway activities shown in gene expres-
sion and methylation data from 37 pathways in case and 36 pathways in control, which
are given in Fig. 4.
Evaluation of pathway-set markers with disease classification
For disease classification, three different types of genetic markers (including the
markers of genes/pathways/pathway-sets) were used and compared in terms of the sen-
sitivity, specificity, and accuracy. In the breast cancer dataset (Dataset 1), 67 differen-
tially expressed genes were identified as gene markers using Limma with p-value < 0.05,
Fig. 2 The heatmap of 500 pathway-set markers identified by our proposed approach from Dataset 1
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Fig. 4 Relationship between pathway activities shown in gene expression and methylation data
a
b
Fig. 3 The heatmap of all the interesting pathway-sets obtained from (a) gene expression data and (b)
methylation data. a includes 116 pathway-sets in control and 380 in case while (b) includes 260 pathway-sets
in control and 290 in case, respectively
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whereas 36 pathway markers were found by GSEA. As pathway-set markers, we used
500 pathway-sets chosen in earlier stage. For classification with pathway-set markers,
we derived the activities of pathway-sets from pathway activity profiles in the similar
way to define pathway activities from gene expression profiles. Table 1 summarizes our
classification results averaged over 8 repetitions with three types of markers (genes,
pathways, pathway-sets) in Dataset 1. According to this table, overall, the pathway-set
markers were superior or very comparable to other markers (genes, pathways) regard-
less of classification method.
For uterine leiomyoma cancer dataset (Dataset 2), we identified 276 differentially
expressed genes (DEGs) from gene expression and 1370 differentially methylated genes
(DMGs) from methylation data using Limma with p-value <0.001, respectively. Among
them, we selected 28 common genes between 276 DEGs and 1370 DMGs as gene
markers. For pathway and pathway-set markers, we used the 48 pathways and 496
pathway-sets identified earlier, respectively. Table 2 shows our classification results in
Dataset 2, which reveals that all the markers are comparable in classification
performance.
In addition, we performed paired t-test to support the claim that the difference in
classification accuracies between biomarkers is significant, as in Table 3. From this
table, it is found that pathway-set markers are significantly superior to gene markers in
Dataset 1 for all 4 classification methods, while showing no significant difference from
gene markers in Dataset 2 except kNN. Also, there was no significant difference be-
tween pathway-set and pathway markers except in kNN. That is, pathway-set markers
are superior or comparable to other biomarkers (genes, pathways) in classification
performance.
Distinctive features of pathway activity networks in case and control samples
To have better understanding of the identified pathway-set markers, we constructed
the pathway activity network (PAN) (See the Method section for details). Based on our
pathway-sets, two different PANs were generated that demonstrate differential pathway
Table 1 Comparison of classification performance with three types of markers in the breast cancer
dataset
Classifiers Markers Sensitivity Specificity Accuracy
kNN genes 93.6 (2.06) 82.56 (3.29) 88.08 (1.94)
pathways 92.44 (1.08) 89.53 (1.76) 90.99 (1.2)
pathway-sets 97.09 (2.06) 90.7 (1.24) 93.9 (1.03)
RF genes 87.21 (1.76) 87.79 (1.08) 87.5 (0.82)
pathways 93.31 (2.62) 92.73 (1.49) 93.02 (1.08)
pathway-sets 93.31 (2.62) 92.73 (1.49) 93.31 (1.03)
SVM genes 86.63 (1.08) 86.63 (2.41) 86.63 (1.52)
pathways 93.9 (1.73) 91.28 (1.08) 92.59 (1.23)
pathway-sets 91.57 (3.27) 92.44 (1.08) 92.01 (1.91)
Naïve Bayes genes 86.63 (1.08) 86.63 (2.41) 86.63 (1.52)
pathways 93.9 (1.73) 91.28 (1.08) 92.59 (1.23)
pathway-sets 91.57 (3.27) 92.44 (1.08) 92.01 (1.91)
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associations appeared in case and control samples, respectively. By doing so, we could
easily capture the distinctive features of pathway activities and their associations shown
in class samples. In the PAN, the thickness of an edge is proportional to the relative
frequency of pathway associations shown in pathway-set markers of class samples. The
size of a node is proportional to the relative significance of corresponding pathway in
the sense of how much distinguishable its activity level is between case and control
samples. Thus, as pathway is more significant, its node size would be larger. Also, the
color of a node indicates the activity type of its corresponding pathway in terms of ex-
pression changes, i.e., the node is displayed in red when its corresponding pathway is
up-regulated under the class condition (case/control) or in blue when it is down-
regulated.
For Dataset 1, we obtained the two PANs shown in case and control samples, as in
Fig. 5. They clearly revealed distinctive features of pathway activities each in case and
control classes. In particular, Fig. 5(a) and (b) show the distinguishable signature of
pathway associations existing only in case PAN and only in control PAN, respectively.
For example, in Fig. 5(a), it is seen that pathway 4 (spliceosome) has significant associa-
tions with many other pathways (including pathways 14, 16, 17, 20, 21, 22, 23, 27, 30,
and etc.), indicating that these associations are observed only in case samples while not
in control samples as in Fig. 5(b). In particular, it is interesting that even if pathway 4
(spliceosome) itself is relatively not that significant in pathway-level analysis, our
pathway-set analysis could newly discover the significance of pathway 4 in the
Table 2 Comparison of classification performance with three types of markers in the uterine
leiomyoma cancer dataset
Classifiers Markers Sensitivity Specificity Accuracy
kNN genes 93.75 92.97 (2.21) 93.36 (1.1)
pathways 92.97 (2.21) 93.75 93.36 (1.1)
pathway-sets 93.75 93.75 93.75
RF genes 90.62 (3.34) 93.75 93.36 (1.1)
pathways 92.97 (2.21) 92.97 (2.21) 92.19 (1.45)
pathway-sets 93.75 92.97 (2.21) 93.36 (1.1)
SVM genes 93.75 92.19 (2.89) 92.97 (1.45)
pathways 92.97 (2.21) 93.75 93.75
pathway-sets 93.75 93.75 93.75
Naïve Bayes genes 93.75 92.19 (2.89) 92.97 (1.45)
pathways 93.75 93.75 93.75
pathway-sets 93.75 93.75 93.75
Table 3 Statistical significance (p-values) of the difference in classification accuracies between
biomarkers in Dataset 1 and Dataset 2
Dataset 1 Dataset 2
pathway-set vs gene pathway-set vs pathway pathway-set vs gene pathway-set vs pathway
kNN 3.316504e-05 0.0005898392 0.01994213 NaN
RF 1.241385e-06 0.3506167 0.1035517 NaN
SVM 5.368579e-05 0.4699636 NaN NaN
Naïve Bayes 5.368579e-05 0.4699636 NaN NaN
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associations with many other pathways. Thus, such distinctive features of pathway asso-
ciations shown in case samples may be possibly good disease signature itself or vital
clues to the disease signature. To verify the biological significance of pathway associa-
tions shown over the PAN, we searched for literatures and found some interesting evi-
dences that pathway 4 (spliceosome) is related to the cause of breast cancer [29].
Moreover, pathway 30 (transcriptional regulation of white adipocyte differentiation)
that is significantly associated with pathway 4 over the PAN is known to have relevance
to breast cancer [30, 31].
For Dataset 2, we obtained the PANs shown in case and control samples of gene ex-
pression data, which are given in Fig. 6. Also, the PANs shown in case and control sam-
ples of methylation data are given in Fig. 7. In Fig. 6, we can see that pathway 9
(CXCR4 pathway) is significantly associated with pathway 21 (insulin receptor recyc-
ling) only in case samples. Whereas, in Fig. 7, it is observed that pathway 35 (double
strand break repair) has some interesting associations with pathway 6 (P53 signaling
pathway) and pathway 48 (intrinsic pathway for apoptosis) only in case samples.
Fig. 5 Differential patterns of PANs in case (left) and control (right) classes from Dataset 1
Fig. 6 PANs differentially shown in case (left) and control (right) class obtained from mRNA expression in
Dataset 2
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Conclusions
In this study, we have focused on identifying interesting pathway-sets that indicate
the distinctive features of the activities of significant pathways and their associa-
tions shown in case and control samples. These pathway-sets were found by con-
sidering sets of significant pathways frequently activated together over class
samples. For this purpose, we utilized an association rule mining approach that
employs the BiMax biclustering method to detect pathway associations with discre-
tized pathway activity profiles. Even if the BiMax method is relatively faster and
more time-efficient than traditional approaches like Apriori algorithm that often
create too many rules and is time-consuming, it still has the practical problem
such that the number of clusters tends to increase drastically as the number of in-
put features (i.e., the number of significant pathways) increases, leading to the rad-
ical increase of corresponding pathway-sets. To handle this situation, we prioritized
the identified pathway-sets using rule interestingness measures and selected top-n
most significant pathway-sets. The chosen pathway-sets performed superior or very
comparable to other biomarkers in disease classification. Moreover, by constructing
pathway activity network from the identified pathway-sets, we could gain deeper
insights into pathway associations differentiating between case and control samples.
However, since our experiments were conducted with only one disease and one
kind of control types, the results we obtained in this study may have some limita-
tion. To strengthen the prominence of our approach, it will be necessary to per-
form additional experiments with wide selection of data, including multiple cancer
and tissue types. Although our work may not cover all aspects of biomarker identi-
fication issues, the methodology used in this study could be still applicable to dis-
cover interesting biomarkers for other diseases, as well as to underpin the
biological mechanisms of target diseases. As future works, we plan to perform
pathway association studies with multiple cancer types. We also plan to work on
identifying disease-specific markers using normal samples of multiple tissue types
in near future.
Fig. 7 PANs differentially shown in case (left) and control (right) classes obtained from DNA methylation in
Dataset 2
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Methods
Data preparation
In the gene expression (or methylation) data, when there are multiple probes corre-
sponding to gene, we used their averaged expression values as an expression value of
the gene. Also, such genes that the variances of their expression values are lower than a
certain threshold were excluded from the data, and zero-mean normalization was ap-
plied to adjust different scales of genes into a common scale. We used MSigDB C2 cu-
rated data to define candidate pathways and found significant (active) pathways among
the candidates by performing GSEA with gene expression or methylation data, in which
two different methods (i.e., SNR and t-test) were used to find differentially expressed
genes. From two GSEA results obtained by SNR and t-test, respectively, common path-
ways were considered as significant pathways.
In case of the uterine leiomyoma cancer datasets (Dataset 2), since it contains gene
expression profiles and DNA methylation data, significant pathways were finally chosen
by taking the union of significant pathways found from gene expression data and from
DNA methylation data, respectively.
Finding pathway-set markers by pathway association analysis
For pathway association analysis, we first obtained pathway activity profiles from
gene expression (or methylation) data by adapting the method used in [23] and
discretized them by assigning either −1 (lowly expressed, down-regulated) or +1
(highly expressed, up-regulated) to each value of pathway activity. Then, these dis-
cretized pathway activity data of +1’s and -1’s were converted into the binarized
data of 0’s and 1’s for biclustering analysis. Specifically, for each n-dimensional
pathway activity vector of +1’s and/or -1’s, we produced a 2n-dimensional binary
vector of 1’s and 0’s by assigning first n bits to the binarization of up-regulated
data (or hyper-methylation data) and other n bits to the binarization of down-
regulated data (or hypo-methylation data), as in Fig. 8. Next, with the binarized
pathway activity data, we performed the BiMax biclustering analysis to generate
such clusters that each cluster should contain at least 2 pathways and as many
samples as satisfying a minimum support threshold. Here the minimum support
specifies the minimum size of samples included in each cluster. For example, if
minimum support is 25%, it means that each cluster should have at least 25% of
class samples or more. As a minimum support threshold increases, the number of
generated clusters would decrease while they would have higher support.
Once all clusters were found for case and control samples, respectively, we examined
each of them to generate association rules. Prior to rule generation, we calculated the
confidence and the lift of each cluster for evaluation, and eventually produced the
Fig. 8 An example of 2n-bit binarized pathway activity vector produced from n-bit discretized pathway
activity vector
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association rules only for the clusters that satisfy the thresholds of confidence ≥0.8 and
lift >1. If a certain cluster were found in the both classes, two association rules are con-
sidered; one for the case and the other for the control. Out of these two rules, the less-
significant rules are eliminated. Then, from all the produced association rules, we
extracted interesting pathway-sets. Figure 9 illustrates an example of interesting
pathway-sets in the rule form of {pathway-set}⇒ {class}, where the constituent path-
ways in a pathway-set are expressed as being up-regulated (↑) or down-regulated (↓).
Disease classification with pathway-set markers
From the pathway-set markers, we obtained pathway-set activity profiles by applying
the method adapted from Lee et al. [23] to pathway activity profiles, and used them for
classification. That is, the activity of pathway-set was defined by combining the activ-
ities of pathways in such a way to have the most discriminative power in the pathway-
set. To calculate discriminant power, we used a statistical test Limma that performs
well regardless of sample size and data distribution.
For classification with pathway-set markers, we employed four classification methods,
including k-nearest neighbor (KNN), support vector machine (SVM), random forest
(RF), and naïve Bayesian classifiers. This task is to predict a target class (control or
case) of a given sample from the distinctive signature shown in identified pathway-set
markers. For performance evaluation, we used 4-fold cross-validation with 8 repetitions
in which each repetition is for random selection in data partitioning, and compared the
averaged classification results over 8 repetitions in terms of sensitivity, specificity, and
accuracy. We also conducted paired t-test between the accuracies of biomarkers (genes,
gene-sets, and pathway-sets) and examined if the difference between classification ac-
curacies is statistically significant.
Construction of pathway activity network from pathway-set markers
For better understanding of the identified pathway-set markers, we constructed
pathway activity network (PAN) in which the nodes represent significant (active)
pathways, the edges represent the associations between active pathways. The thick-
ness of an edge represents the relative frequency of pathway associations shown in
the identified pathway-set markers. Also, the size of a node represents the relative
significance of pathway that is defined as –log2 (p-value) when p-value is a
Fig. 9 Example of interesting pathway-sets in the rule form for each class, in which an upward pointing
arrow (or downward pointing arrow) indicates up-regulation (or down-regulation) of each pathway
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statistical significance of the difference in its activity level between case and control
classes. The size of a node represents the relative significance of corresponding
pathway in the sense of how much distinguishable its activity level is between case
and control samples. The PAN can be drawn separately for each class (case or
control), which shows distinctive features of pathway activities and their associa-
tions in case or control samples.
Additional files
Additional file 1: (a). Significant pathways in Dataset 1. (b). Top 10 interesting pathway-sets obtained from
Dataset 1. (PDF 199 kb)
Additional file 2: Significant pathways in Dataset 2 and 3. (PDF 103 kb)
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